Page 31 - Read Online

da Fonseca et al. Hepatoma Res 2019;5:37 I http://dx.doi.org/10.20517/2394-5079.2019.012 Page 13 of 13

48. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, et al. Tremelimumab in combination with ablation in
patients with advanced hepatocellular carcinoma. J Hepatol 2017;66:545-51.
49. Wainberg ZA, Segal NH, Jaeger D, Lee KH, Marshall J, et al. Safety and clinical activity of durvalumab monotherapy in patients with
hepatocellular carcinoma (HCC). J Clin Oncol 2017;35:4071.
50. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
51. FDA grants accelerated approval to nivolumab for HCC previously treated with sorafenib. Available from: https://www.fda.gov/drugs/
informationondrugs/approveddrugs/ucm577166.htm. [Last accessed on 10 Oct 2019]
52. Bristol-Myers Squibb Announces Results from CheckMate -459 Study Evaluating Opdivo (nivolumab) as a First-Line Treatment for
Patients with Unresectable Hepatocellular Carcinoma. Available from: https://news.bms.com/press-release/bmy/bristol-myers-squibb-
announces-results-checkmate-459-study-evaluating-opdivo-nivol. [Last accessed on 10 Oct 2019]
53. Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, et al. CheckMate 459: A randomized, multi-center phase III study of nivolumab
(NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann Oncol
2019;30:mdz394.029
54. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma
previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.
55. FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma. Available from: https://www.fda.gov/Drugs/
InformationOnDrugs/ApprovedDrugs/ucm625705.htm. [Last accessed on 10 Oct 2019]
56. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, et al. Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs
best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol 2019;37:abstract4004.
57. Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients
(pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040. J Clin Oncol 2019;37:4012.
58. Kelley RK, Abou-Alfa GK, Bendell JC, Kim TY, Borad MJ, et al. Phase I/II study of durvalumab and tremelimumab in patients with
unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. J Clin Oncol 2017;35:4073.
59. Zhou Y, Xu X, Ding J, Jing X, Wang F, et al. Dynamic changes of T-cell subsets and their relation with tumor recurrence after
microwave ablation in patients with hepatocellular carcinoma. J Cancer Res Ther 2018;14:40-5.
60. Pishvaian MJ, Lee MS, Ryoo B, Stein S, Lee K, et al. Updated safety and clinical activity results from a phase Ib study of
atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Available from: https://oncologypro.esmo.org/Meeting-Resources/
ESMO-2018-Congress/Updated-safety-and-clinical-activity-results-from-a-Phase-Ib-study-of-atezolizumab-bevacizumab-in-
hepatocellular-carcinoma-HCC. [Last accessed on 10 Oct 2019]
61. FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced
or metastatic hepatocellular carcinoma (HCC). Available from: https://www.roche.com/media/releases/med-cor-2018-07-18.htm. [Last
accessed on 10 Oct 2019]
62. Ikeda M, Sung MW, Kudo M, Kobayashi M, Baron AD, et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in
patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol 2018;36:abstract4076.
63. Kudo M, Motomura K, Wada Y, Sakamoto Y, Kurosaki M. First-line avelumab + axitinib in patients with advanced hepatocellular
carcinoma: results from a phase 1b trial (VEGF Liver 100). J Clin Oncol 2019;37:abstract4072.
64. Stein S, Pishvaian MJ, Lee MS, Lee KH, Hernandez S, et al. Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase
Ib study in hepatocellular carcinoma (HCC). J Clin Oncol 2018;36:4074.
65. El-Khoueiry AB, Melero I, Yau TC, Crocenzi TS, Kudo M, et al. Impact of antitumor activity on survival outcomes, and
nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of
CheckMate-040. J Clin Oncol 2018;36:475.
66. Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol
2016;17:e542-51.
67. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.